Management of iron deficiency anemia with ferric carboxymaltose during pregnancy
There has been a dearth of scientific statistics aiding the
efficacy and protection of ferric carboxymaltose (FCM) infusion in pregnant Indian girls
This was converted to a subgroup analysis of the PROMISE trial,
which was previously conducted in a real-world, multicentre,
Among the 1,191 protected pregnant women in the subgroup
examined, IV FCM significantly increased hemoglobin (Hb)
serum ferritin to 30.03 μg/L at four weeks (P < 0.001 for both). Hb
expanded to 3.6 g/dL (P<0.001) and serum ferritin with the help of sixteen.
serum ferritin to 30.03 μg/L at four weeks (P < 0.001 for both). Hb
expanded to 3.6 g/dL (P<0.001) and serum ferritin with the help of sixteen.
Ninety-six μg/L (P = 0.12), all of which have been statistically of
good size will increase in 103 pregnant women with excessive ADI
Significant increases in serum ferritin using 33 μg/L and Hb up to 2.74
g/dL (P<0.001 for each) were observed in 978 pregnant women with mild IDA.
mplicit corpuscular volume, mean corpuscular hemoglobin,
hematocrit, and red cell dependency were greatly increased (P < zero.001 for all)
Need More Stories
Learn more